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Abstract
Adolescents with attention-deficit/hyperactivity disorder (ADHD) are at increased risk of developing substance use disorders 
(SUDs) and nicotine dependence (ND). It remains unclear whether and how stimulant treatment may affect this risk. We 
aimed to investigate how stimulant use profiles influence the risk of SUDs and ND, using a novel data-driven community 
detection analysis to construct different stimulant use profiles. Comprehensive lifetime stimulant prescription data and data 
on SUDs and ND were available for 303 subjects with ADHD and 219 controls, with a mean age 16.3 years. Community 
detection was used to define subgroups based on multiple indicators of treatment history, start age, treatment duration, 
total dose, maximum dose, variability, stop age. In stimulant-treated participants, three subgroups with distinct medication 
trajectories were distinguished (late-and-moderately dosed, n = 91; early-and-moderately dosed, n = 51; early-and-intensely 
dosed, n = 103). Compared to stimulant-naïve participants (n = 58), the early-and-intense treatment group had a significantly 
lower risk of SUDs and ND (HR = 0.28, and HR = 0.29, respectively), while the early-and-moderate group had a significantly 
lower risk of ND only (HR = 0.30). The late-and-moderate group was at a significantly higher risk of ND compared to the 
other two treatment groups (HR = 2.66 for early-and-moderate, HR = 2.78 for early-and-intense). Our findings show that in 
stimulant-treated adolescents with ADHD, long-term outcomes are associated with treatment characteristics, something that 
is often ignored when treated individuals are compared to untreated individuals.
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Abbreviations
ADHD  Attention-deficit/hyperactivity disorder
CD  Conduct disorder
GAM  General additive model
HR  Hazard ratio
IQ  Intelligence quotient
MPH  Methylphenidate
ND  Nicotine dependence
ODD  Oppositional defiant disorder
SD  Standard deviation
SES  Socioeconomic status
SUDs  Substance use disorders
95% CI  95% Confidence interval
Introduction
Individuals with attention-deficit/hyperactivity disorder 
(ADHD) are at increased risk of developing substance use 
disorders (SUDs) and of starting smoking [1]. Stimulant 
treatment is the first choice pharmacological treatment of 
ADHD [2] because it has been proven efficacious in reduc-
ing core symptoms of the disorder [3, 4]. In recent years, 
concerns that stimulant treatment might increase SUDs and 
smoking in ADHD have been invalidated [5, 6]. One meta-
analysis [6] found that stimulant treatment did not affect 
the development of SUDs or nicotine dependence (ND), 
whereas the other meta-analysis [5] found a protective effect 
of stimulants on tobacco use. Possibly, stimulant treatment 
may have a protective effect in earlier phases of smoking, 
but not in later stages (i.e., ND). These inconclusive results 
may be explained by differences in outcome measure sever-
ity (smoking vs ND), or indicate unidentified moderators on 
the development of SUDs and smoking.
Studies have reported earlier initiation of stimulant treat-
ment [7–9] and longer duration of stimulant use [10] as pos-
sibly enhancing the protective effect on the development of 
SUDs; however, other studies did not replicate these find-
ings [11, 12]. Preclinical studies suggest that the brain may 
be more sensitive to the effect of stimulants during adoles-
cence (i.e., critical or sensitive age periods) [13]. A recent 
study predicted substance-related behavior from both age 
of treatment onset and duration of treatment, and found that 
short, late-onset stimulant treatment increased the risk of 
SUDs. Unfortunately, this study did not account for ADHD-
severity, a factor related to both stimulant treatment and the 
risk of SUDs [14], and looked at both factors separately. In 
contrast, earlier onset of use [7–9], longer duration [10], 
and higher treatment continuity [5] could have positive 
long-term effects on SUDs and smoking. Previous studies 
have looked at these factors individually, but to the best of 
our knowledge, no studies have investigated these factors in 
concert to assess their joint predictive power on SUDs and 
smoking.
The objective of this study is to investigate how stimu-
lant use profiles are associated with the risk of SUDs and 
ND. Here, we used a novel technique of community detec-
tion to identify distinct subgroups of patients with ADHD 
based on multiple indicators of stimulant treatment history 
(i.e., stimulant use profiles). This technique has previously 
been used in a partly overlapping, but smaller sample where 
we, successfully predicted increased brain activation dur-
ing reward receipt in those treated early and intensely [15], 
in a brain area important in the development of SUDs and 
smoking. With this study, we build on the previous results 
comparing stimulant-treated subjects with stimulant-naïve 
and controls [16]. Start age, treatment duration, total dose, 
maximum dose, variability, and stop age were derived from 
highly detailed individual pharmacy transcripts. We hypoth-
esized that adolescents with ADHD who started treatment 
at younger age, and were treated longer and at a more stable 
dose, would have a lower risk of SUDs and ND compared 
to adolescents with a history of later, lower dose, and vari-
able treatment.
Methods
Participants
Participants were selected from the Dutch part of the Inter-
national Multicenter ADHD Genetics (IMAGE) study [17]. 
Data collection of IMAGE took place between 2003 and 
2006. ADHD families were recruited from outpatient clin-
ics and included at least one child aged 5–17 years with 
combined-type ADHD and at least one biological sibling 
regardless of ADHD diagnosis. Exclusion criteria apply-
ing to all participants included autism, epilepsy, IQ < 70, 
brain disorders, and any single gene disorder associated with 
externalizing behaviors that might mimic ADHD (e.g., frag-
ile-X). Additionally, control families were recruited from 
primary and high schools from similar geographical regions 
as participating ADHD families.
For the current study, participants were followed-up on an 
average 4.2 (SD 0.7) years after the enrolment in the study 
(data collection 2008–2009). Ethical approval for the study 
was obtained from National Institute of Health registered 
ethical review boards and local ethical review boards and 
written informed consent was obtained from all participants 
and/or their parents. During this follow-up 511 participants 
with ADHD and 220 control participants above the age of 
12 participated (84.17% of the original ADHD sample and 
76.38% of the original control sample).
The current paper includes all participants above the age 
of 12 at follow-up with ADHD and with information on 
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substance use and pharmacy data (n = 303, of which 58 par-
ticipants were stimulant-naïve) at follow-up. No differences 
were found between those participants with ADHD success-
fully followed-up and those lost to follow-up on ADHD-
severity, impairment, age (p > 0.24 for all measures), sex 
(p = 0.73), ODD (p = 0.85) or CD (p = 0.58). A total of 219 
control subjects with no history or family history of psychi-
atric disorders were available to study differences between 
participants with ADHD (trajectory groups) and controls. 
Most commonly prescribed stimulants were immediate-
release methylphenidate (87.5%), extended-release meth-
ylphenidate (70.1%), and dexamphetamine (8.6%); other 
non-stimulant medication was commonly prescribed, and 
could thus not be excluded, but sensitivity analysis will be 
done. Most commonly prescribed non-stimulant medications 
were low-dose atypical antipsychotics, mostly risperidone 
(21.7%), atomoxetine (14.8%), anxiolytics/benzodiazepines 
(6.1%), and antidepressants (7.3%).
Measurements
Diagnostic assessment
Assessment of  ADHD, oppositional defiant disorder, 
and  conduct disorder at  baseline At study entry, par-
ticipants from ADHD families were screened for ADHD, 
using standard procedures of the IMAGE project (see sup-
plement). In short, DSM-IV diagnoses [18] and symptom 
counts (i.e., severity) for ADHD, conduct disorder (CD) 
and oppositional defiant disorder (ODD) were based on 
the Parental Account of Childhood Symptoms interview in 
combination with the Long Version of the Conners Parent 
and the Teacher Rating Scales. All subjects with ADHD met 
full DSM-IV criteria for ADHD.
Substance use disorder at  follow‑up At follow-up, assess-
ment of SUDs (both alcohol and drug use disorder), and 
smoking were obtained using the Diagnostic Interview 
Schedule for Children (DISC-IV-P), Alcohol Use Disorders 
Identification Test (AUDIT), Drug Abuse Screening Test–
20 (DAST), and Fagerström Test for Nicotine Dependence 
(FTND). SUDs were defined as a positive score on either 
the DISC-IV-P, AUDIT, or DAST (for details, see supple-
ment). As previous meta-analyses [5, 6] found contrasting 
results concerning smoking and stimulant treatment, we 
operationalized smoking in two ways: (1) daily smoking of 
less than 10 cigarettes, and (2) ND (a score of 6 or higher 
on the FTND, or a positive score on the tobacco module of 
the DISC-IV-P).
Stimulant medication use Lifetime pharmacy transcripts 
were collected at follow-up. On an average, pharmacy tran-
scripts covered 69.1% of lifetime. When pharmacy data 
were missing, self-report data were used (also see Supple-
ment). Pharmacy data were used to reconstruct treatment 
trajectories per participant with high temporal resolution. 
Stimulant trajectories in mg per day were constructed for 
each day between dates of birth and follow-up. To reduce 
effects of high frequency dose changes (inherent to the high 
temporal resolution), we derived smoothed treatment trajec-
tories as well using a generalized additive model (GAM) 
in R [19, 20]. The following measures were extracted from 
either the raw treatment trajectories or the fitted GAM mod-
els: start age (raw trajectory); treatment duration relative 
to age (duration [GAM model] divided by age minus the 
earliest start age within the sample, i.e., 2.3  years); total 
dose [raw trajectory] relative to age; maximum dose (GAM 
model); variability (SD) of the dose (GAM model); and stop 
age (raw trajectory) (see Fig. 1 for an example of a single 
subjects data).
Statistical analyses
The six variables describing individual medication trajecto-
ries were entered in a Louvain community detection algo-
rithm in R3.2.2 [21, 22] to identify distinct subgroups of 
stimulant-treated patients with ADHD based on treatment 
profiles [23]. The algorithm classifies participants such that 
similarities within groups as well as differences between 
groups are maximized. The modularity (Q) quantifies the 
degree to which separation between subgroups is achieved 
(Q of zero indicates no subgroups, and a Q of one perfect 
segregation between subgroups). The algorithm iterates 
until Q no longer increases, indicating the solution will not 
improve with further iterations. Stimulant-naïve subjects 
were manually added as separate subgroup.
Comparisons between medication subgroups were per-
formed using SPSS 22 (IBM SPSS Statistics version 22). 
Differences between groups in gender, age, IQ, ADHD-
severity, and CD comorbidity were examined using analysis 
of variance and Chi square tests. We examined differences in 
the development of SUDs and smoking (daily smoking vs. 
ND) in the subgroups using cox proportional hazard models. 
The models used age at first substance or nicotine use as the 
survival time for the cases (classified as having an SUD and/
or daily smoking/ND) and current age as the time of censor-
ing for the non-cases. Correction for clustered (family) data 
was done using robust standard errors [24].
Sensitivity analyses were performed following significant 
results, to assess the effect of known confounders (i.e., SES, 
ADHD-severity, IQ, CD and the use of non-stimulants) and 
to see how medication groups differed from controls, (these 
analyses are described in full in the supplement). Matched 
group analyses (based on age and hyperactive symptoms) 
were performed to rule out the effect of these variables.
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Results
Community detection
The community detection procedure yielded three medi-
cation subgroups of stimulant-treated patients (Fig. 2; 
Q = 0.61). The fourth medication subgroup was manu-
ally added, namely the stimulant-naïve group. Bootstrap 
analyses (non-parametric bootstrap with 1000 replications) 
showed high stability of the three-class solution, which 
was identified in 94.8% of the runs, with mean Q = 0.60 
(SD = 0.02; see Supplement). The largest group (n = 103) 
was characterized by young onset of treatment age, varia-
ble trajectory of medication use with a long duration, high 
total and high maximum dose, and young age at treatment 
offset (also see Table 1 and Fig. 2 for characteristics of the 
groups). We referred to this group as ‘early-and-intense 
use’ subgroup. The second group (n = 91) was character-
ized by late-onset age of treatment, short duration, and 
Fig. 1  Example of a single 
subjects’ data. Data from a sin-
gle subject with a fitted GAM 
model. GAM generalized addi-
tive models. Duration of use, 
maximum dose and variability 
of dose are based on the GAM 
model. Medication use = aver-
age monthly daily dose
Fig. 2  Community detection outcomes. This figure depicts the three 
medication subgroups that were defined by the community detec-
tion algorithm: (1) a late-and-moderate use group characterized by a 
late onset of treatment, short duration, and moderate total dose and 
maximum use, (2) a early-and-moderate use group characterized by a 
young onset age, a long duration of use, and a late offset of treatment 
age, and (3) early-and-intense use group characterized by a young 
onset of treatment age, a variable trajectory of medication use with a 
long duration, high total dosage, high maximum dosage and early age 
at treatment offset. AOO stimulant medication offset, VAR variability 
of dose (SD), DUR duration of use, TOT total dose, MAX maximum 
dose, SA stop age
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moderate total dose and maximum use, referred to as ‘late-
and-moderate use’ subgroup. The third group (n = 51) was 
characterised by young treatment onset age, long duration, 
and late offset age, referred to as ‘early-and-moderate use’ 
subgroup. The fourth subgroup was comprised of the 58 
stimulant-naïve subjects.
Characteristics of the four subgroups are given in Table 1. 
There were no differences between the four medication 
subgroups in percentage of males, CD, IQ, or number of 
inattentive symptoms at baseline. The early-and-intense 
use subgroup was significantly younger and had more 
hyperactive-impulsive symptoms at baseline compared to 
the other medication subgroups. Subgroups of subjects were 
selected from the empirically derived medication subgroups 
to yield four groups equivalent in sample size (n = 51), age, 
and hyperactivity-impulsivity (see Supplement for additional 
details). The medication groups were matched post hoc on 
age and hyperactivity/impulsivity symptoms at baseline 
(information on exact selection procedures can be found in 
the Supplement).
The stimulant-treated subgroups did not differ in per-
centage of anxiolytics/benzodiazepines or antidepressants 
Table 1  Subject Characteristics
0 = stimulant-naïve subgroup, 1 = late-and-moderate use subgroup, 2 = early-and-moderate use subgroup, 3 = early-and-intense use subgroup, 
4 = controls, SES = socioeconomic status (based on average years of parents’ education). ODD, CD, and ADHD symptoms were measured at 
baseline. Pairwise comparisons were performed with Tukey with equal variances or Dunnett’s T3 when variances were unequal
SUDs substance use disorders
a Daily smoking = daily smoking of at least 1 cigarette per day
b In years
c Corrected for age of possible use, d derived from the GAM model
Stimulant-
Naïve 
(n = 58)
Late-and-
moderate use 
(n = 91)
Early-and-
moderate use 
(n = 51)
Early-and-
intense use 
(n = 103)
Controls 
(n = 219)
Test-value P value Contrasts
Gender, n males 
(%)
44 (75.9) 68 (73.9) 42 (82.4) 89 (86.4) 88 (40.2) χ2 = 90.06 <0.001 4 < (0 = 1=2 = 3)
Age at follow-
up
17.22 (2.68) 16.77 (2.52) 16.09 (2.11) 15.28 (2.07) 16.34 (2.52) F = 7.79 <0.001 0 = 1=2 = 4, 
3 < (0 = 1=4), 
3 = 2
Age at baseline 12.60 (2.72) 12.29 (2.51) 11.53 (2.03) 10.75 (2.17) 12.60 (2.65) F = 11.23 <0.001 0 = 1=2 = 4, 
3 < (0 = 1=4), 
3 = 2
IQ 98.4 (15.22) 99.53 (12.96) 96.97 (13.01) 100.95 (13.65) 105.56 (9.52) F = 6.41 <0.001 4 > (0 = 1=2 = 3)
Hyperactive 
symptoms
7.08 (2.23) 7.83 (1.4) 7.88 (1.47) 8.25 (1.15) – F = 6.42 <0.001 3 > 0, 0 = 1=2, 
1 = 2=3
Inattentive 
symptoms
8.04 (1.24) 7.90 (1.69) 8.20 (0.98) 8.07 (1.07) – F = 0.79 0.50 0 = 1=2 = 3
ODD, n (%) 16 (30.2) 25 (33.3) 24 (50.0) 35 (43.2) – χ2 = 5.79 0.12 0 = 1=2 = 3
CD, n (%) 10 (18.9) 17 (22.7) 7 (14.9) 15 (18.5) – χ2 = 1.17 0.76 0 = 1=2 = 3
SES 12.22 (2.75) 11.20 (1.94) 11.26 (2.39) 11.32 (2.04) 12.58 (2.66) F = 8.03 0.001 0 = 1=2 = 3,0 = 4, 
4 > (1,2,3)
Age of  onsetb 11.47 (2.39) 7.73 (1.32) 7.09 (1.53) F = 145.08 <0.001 1 > (2 = 3)
Stop  ageb 15.73 (2.58) 15.31 (2.42) 14.66 (2.34) F = 4.79 0.009 1 > 3 1 = 2, 2 = 3
Durationc, d 0.73 (0.06) 0.87 (0.05) 0.87 (0.7) F = 150.45 <0.001
Variabilityd 98.93 (101.15) 70.49 (51.73) 334.08 (204.62) F = 82.26 <0.001 3 > (1 = 2)
Maximum dose 
in  mgd
23.93 (14.61) 22.62(9.81) 53.35(17.89) F = 114.01 <0.001 3 > (1 = 2)
Cummulative 
 usec
5.70(4.05) 8.54 (4.37) 18.51 (7.41) F = 129.04 <0.001 1 < 2<3
SUDs, n (%) 19 (32.8) 23 (25.8) 12 (23.5) 8 (7.8) 26 (11.9)
Daily  Smokinga, 
n (%)
23 (39.7) 28 (30.8) 14(27.5) 28 (27.2) 40 (18.3)
Nicotine 
Dependence, 
n (%)
11 (19.0) 14 (15.7) 3(5.9) 5 (4.9) 6 (2.7)
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prescribed (p > 0.05), but the early-and-moderate use sub-
group was prescribed atomoxetine more often compared 
to the early-and-intense use subgroup (24.3% vs. 9.8%), 
and the early-and-moderate subgroup was prescribed 
more atypical antipsychotics compared to the late-and-
moderate use subgroup (33% vs. 17.6%).
Substance use disorder
At follow-up, the medication subgroups differed in the 
number of participants with SUDs (Wald χ2 = 25.06, 
p < 0.001; see Table 2 and Fig. 3). The early-and-intense 
use subgroup was at the lowest risk of developing SUDs 
compared to the three other subgroups, but no differences 
were found between the other subgroups. Sensitivity anal-
yses with matched groups (matched on age and hyperac-
tivity/impulsivity symptoms) confirmed that the lower 
risk for SUDs found in the early-and-intense subgroup 
was not due to age (also see supplementary Table S2 and 
Figure S1). Sensitivity analyses showed that the differ-
ence in subgroups in SUDs was not due to SES, CD, IQ, 
ADHD-severity or non-stimulants. Furthermore, sensitiv-
ity analyses showed that the early-and-intense subgroup 
was at comparable risk of developing SUDs to controls, 
but the no stimulant group (HR 2.03, 95% CI 1.53–2.68), 
late-and-moderate group (HR 1.65, 95% CI 1.13–2.41), 
and the early-and-moderate group (HR 1.74, 95% CI 
1.40–2.16) were at significantly higher risk compared to 
controls (also see Table S2).
Smoking
Daily smoking
No differences were found between any of the medication 
subgroups in the risk of daily smoking (Wald χ2 = 4.71, 
p = 0.19; see Table and right panel of Fig. 4).
Nicotine dependence
Significant differences between the medication subgroups 
were found in the risk of developing ND (Wald χ2 = 14.98, 
p = 0.002; see Table 2 and Fig. 4). The early-and-intense 
use and early-and-moderate use subgroups were at lower 
risk of developing ND compared to the late-and-moderate 
use and stimulant-naïve subgroups. The early-and-intense 
use and the early-and-moderate use subgroups did not dif-
fer in their risk, neither did the late-and-moderate use nor 
the stimulant-naïve subgroups. Sensitivity analyses con-
firmed that the lower risk for nicotine dependence found 
in the early-and-intense subgroup was not due to age (also 
Table 2  Hazard ratios for the analyses comparing the medication subgroups
Daily smoking = daily smoking of at least 1 cigarette. Bold numbers indicate significance at p < 0.05
a No significant group effect
Late-and-
moderate use vs. 
naïve
Early-and-moder-
ate use vs. naïve
Early-and-intense 
use vs. naïve
Late-and-moderate 
use vs. early-and-
intense use
Early-and-moderate 
use vs. early-and-
intense use
Late-and-
moderate use 
vs. early-and-
moderate use
HR P HR P HR P HR P HR P HR P
SUDs 0.74 0.19 0.73 0.16 0.28 <0.001 2.70 <0.001 2.66 <0.001 1.01 0.96
Daily  smokinga 0.84 0.36 0.92 0.70 1.23 0.26 0.68 0.04 0.75 0.17 0.91 0.67
Nicotine dependence 0.81 0.34 0.30 0.016 0.29 0.001 2.78 0.009 1.04 0.94 2.66 0.045
Fig. 3  Cumulative lifetime risk for any substance use disorder. One 
minus survival curve estimated with cox proportional hazard model 
for development of SUDs (any alcohol or drug use disorder) in sub-
jects with ADHD with age of first substance use on the x axis
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see supplementary Table S2 and Figure S1). Furthermore, it 
was shown that effects were not dependent on SES, CD, IQ, 
ADHD-severity or non-stimulants. We found that the early-
and-moderate group was at higher risk compared to healthy 
controls (HR 3.16, 95% CI 1.63–6.14). The late-and-moder-
ate (HR 10.21, 95% CI 6.99–14.92) and the stimulant-naïve 
groups were also at higher risk from controls (HR 9.91, 95% 
CI 7.26–13.52) (a full description of the sensitivity analyses 
can be found in the supplement).
Discussion
We aimed to examine the association between stimulant 
medication and the development of SUDs and smoking in 
individuals with ADHD using community detection to con-
struct stimulant use profiles from highly detailed pharmacy 
records. This allowed us to look at stimulant treatment his-
tory in a new manner. We hypothesized that adolescents 
with ADHD who started treatment at younger age and were 
treated longer at a more stable dose, would have a lower 
risk of SUDs and smoking compared to adolescents with a 
history of later, lower dose and variable treatment. We con-
firmed our hypothesis and found that those individuals with 
ADHD who received treatment at a young age and with a 
high dose, were at a lower risk of developing SUDs and ND, 
but those who received treatment at a later age with a lower 
dose were not. This shows that, when looking at stimulant 
treatment effects, multiple indicators of stimulant medica-
tion use should be taken into account.
The current study significantly advances prior studies by 
being the first to look at multivariate profiles of medication 
use using highly detailed pharmacy records, as opposed to 
prior studies looking at a global measure of medication use 
(yes/no) using self-report scales. Our findings are in line 
with prior studies looking at indicators of medication use 
reporting that treatment duration [14] and age of treatment 
onset [7, 9] affect the development of SUDs and ND. In 
addition to these treatment characteristics, our data suggest 
that cumulative dose, maximum dose, and dose variability 
also play a role in the development of addictive disorders in 
ADHD. More specifically, confirming our hypothesis, we 
found that multivariate profiles characterized by a young 
start age of medication, a high maximum and cumulative 
dose are associated with lower risks of SUDs and ND in 
individuals with ADHD.
Our findings regarding smoking showed a distinction 
between daily smoking and ND. Whereas the early-and-
intense group (characterized by a young onset of treatment 
age, a variable trajectory of medication use with a long dura-
tion, high total dosage, high maximum dosage and early age 
at treatment offset) and early-and-moderate group (charac-
terized by a young onset age, a long duration of use, and a 
late offset of treatment age) were at lowest risk of developing 
ND, the risk of daily smoking was unaffected by stimulant 
use profile. Furthermore, these findings show the need to 
Fig. 4  Cumulative lifetime risk for smoking. One minus survival curve estimated with cox proportional hazard model for development of smok-
ing in subjects with ADHD with age of first cigarette use on the x axis. Left panel: daily smoking, right panel: nicotine dependence
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take severity of nicotine use into account in future studies. 
A possibility could be that early in the trajectory of ND, 
stimulant use does not have an effect, but in the later phases 
(i.e., ND) it does. However, this seems unlikely, as previ-
ous studies have suggested a delay in onset of substance-
related disorders as a consequence of stimulant use, with 
much larger effects of stimulant use on the development in 
adolescence [11, 25, 26] than in adulthood [27, 28]. How-
ever, to make conclusive inferences a later follow-up of the 
current sample is necessary.
In studies of long-term medication effects such as ours, 
that are inevitably observational, one should be wary of 
potential confounding by unmeasured variables (i.e., endo-
geneity). As an example, unmeasured parental characteris-
tics rather than stimulant treatment may account for some of 
the differences regarding SUD and ND between treatment 
groups. Similarly, we cannot rule out the possibility that 
the early-and-intense use and the early-and-moderate use 
subgroups differed from the late-and-moderate use group 
with regard to treatment response or factors associated with 
MPH response (e.g., genetic predispositions), which in 
turn may drive the association with SUDs and ND. Treat-
ment response was not assessed in the current study. One 
may argue, however, that treatment response is most likely 
associated with treatment duration rather than with age of 
treatment onset. We recommend future studies of long-term 
stimulant outcomes to take treatment response into account.
The current study has several strengths. First, we intro-
duce a novel approach of looking at stimulant treatment 
history that allows integrated analysis of multiple related 
treatment parameters. This data-driven approach resulted in 
distinct and ecologically valid subgroups, that had predic-
tive validity with regard to important long-term outcomes. 
Second, we had access to extensive and highly detailed phar-
macy records for the majority of our patients with ADHD. 
Third, unlike many previous studies of tobacco use, we dis-
tinguished between smoking and ND and found that indeed 
the effects of stimulant treatment on these two outcomes 
are not the same. Some limitations should be noted as well. 
Long-term outcomes of stimulant medication can only be 
studied using naturalistic longitudinal studies, that are inevi-
tably at risk for endogeneity, making inferences about cau-
sality impossible. Second, we did not have the opportunity 
to distinguish between different SUDs, or SUDs of differ-
ent severity, in a similar fashion as we did for smoking and 
ND, as the numbers of drug use disorders were low in our 
sample. While the exactness of pharmacy records were very 
high detailed and gave us the possibility to use community 
detection, we cannot assure that medications picked up from 
the pharmacy were actually taken by the individual. Further-
more, our sample is a clinical sample, and we can only draw 
conclusion on those subjects in clinical practice. As is com-
mon with clinical samples, our ADHD sample contains more 
males than our controls. While we statistically corrected for 
this, this could have clouded our results. We feel that our 
results are meaningful since our ADHD sample is repre-
sentative of those seeking help for their problems. Addi-
tionally, comorbidities are common in those seeking help, 
and while disruptive behavioral problems are most common, 
other comorbidities are frequent, and should be taken into 
account in future studies. Especially since treatment effects 
can be different in different comorbid subgroups (e.g., [29]). 
Of note, factors associated with early-and intense-treatment, 
such as higher ADHD-severity and higher levels of CD, are 
both also associated with a higher risk of SUDs. Interest-
ingly, this group was associated with a lower risk of SUDs 
and ND. Furthermore, we did not have further information 
on treatment response and tolerability of treatment, and for 
this reason we recommend future studies to take these into 
account. Finally, no data were available regarding psycho-
social interventions; if the reduced risk of SUDs reported 
in this study is associated with a reduction in symptoms of 
ADHD (caused by the use of stimulants), one would expect 
to find other treatments with the potential to lower ADHDs 
core symptoms, such as effective psychosocial interventions, 
to have a protective effect as well.
Conclusion
In conclusion, we add to current literature by showing that, 
in stimulant-treated patients with ADHD, there are distinct 
trajectories of medication use that are differentially related to 
the risk for SUDs and ND. There is evidence to support the 
idea that untreated ADHD is related to worse outcomes than 
treated ADHD [30–32]. Here, we corroborate this evidence, 
and expand on this by showing that a medication profile 
characterized by a late start age, low dose, and low dura-
tion of stimulant treatment also has worse outcomes com-
pared to medication profiles with an early start age, high or 
moderate dose, and long duration of stimulant treatment. 
We want to emphasize the importance of optimal titration 
and proper monitoring of stimulant medication in the treat-
ment of ADHD; stimulant treatment should be at adequate 
dosages to reduce the risk of SUDs and ND as negative 
long-term outcomes associated with ADHD. Furthermore, 
our results show an association between starting stimulant 
treatment at an early age and a reduced risk of develop-
ing negative long-term outcomes. Importantly, long-term 
outcomes of stimulant-treated adolescents with ADHD are 
associated with treatment characteristics, something that 
is often ignored when treated individuals are compared to 
untreated individuals.
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